Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

Uncontrolled study (n=35) found capivasertib confirmed a clinically significant overall response rate of 28.6% in tumours of this genetic profile (multiple histology). One patient had a complete response. Treatment was discontinued because of adverse events in 31% of patients.

Source:

JAMA Oncology